Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Corcept Therapeutics Incorporated

Corcept Therapeutics ($CORT) announced an update on their ongoing clinical study. Study OverviewThis study, officially titled “A Phase 1b/2, Open-L...

Corcept’s Nenocorilant Combo Study Moves Forward, Expanding Its Oncology Ambitions

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Corcept Therapeutics (CORT – Research Report), Intuitive Surgical...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Corcept Therapeutics (CORT), Intuitive Surgical (ISRG) and Vertex Pharmaceuticals (VRTX)

Unusual trading volume signals that a stock is moving well above or below its average activity, often driven by major news, upcoming catalysts, or ...

Current Quarter	$0.27	Next Quarter	$-0.26
Current Year	$0.89	Next Year	$0.84
QoQ Growth	-196.3%	YoY Growth	-5.6%
3Y EPS CAGR	+11.7%	Target Price	$94.20
Consensus	Buy	Upside	+133.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CORT	$40.32	-0.96%	781.42K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CORT	$40.32	-1.0%	781.42K
3
4
5
6

CORT

CORT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Corcept Therapeutics Incorporated Data in Excel

Get Corcept Therapeutics Incorporated Data in Excel